Biofrontera (ETR:B8F) shares are up today after the said it won pre-market approval from the FDA for its drug-device combination treatment for a type of sun-induced skin cancer. Leverkusen, Germany-based Biofrontera said the approval covers its Ameluz drug and BF-RhodoLED medical device for what it calls “photodynamic therapy” to treat mild to moderate actinic keratosis of the face […]